INT119646

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.13
First Reported 2004
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 3.30
Pain Relevance 0.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (FCER2) plasma membrane (FCER2)
Anatomy Link Frequency
mast cells 2
macrophages 1
lymphocytes 1
FCER2 (Homo sapiens)
Pain Link Frequency Relevance Heat
corticosteroid 56 99.28 Very High Very High Very High
Inflammatory mediators 3 89.36 High High
Central nervous system 13 85.32 High High
headache 6 76.88 Quite High
cytokine 19 75.20 Quite High
Inflammation 12 67.36 Quite High
Codeine 4 25.00 Low Low
agonist 9 5.00 Very Low Very Low Very Low
Spinal cord 2 5.00 Very Low Very Low Very Low
imagery 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Anaphylaxis 9 99.58 Very High Very High Very High
Asthma 168 97.96 Very High Very High Very High
Malaria 59 94.76 High High
Lymphatic System Cancer 46 91.08 High High
INFLAMMATION 15 88.96 High High
Hypersensitivity 12 83.24 Quite High
Cancer 15 79.92 Quite High
Convulsion 3 77.28 Quite High
Headache 6 76.88 Quite High
Chronic Lymphoid Leukemia 2 73.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The lymphocytes express B-cell markers (CD19, CD20, and CD79a) and are negative for CD3, CD5, CD10, CD23, and cyclin D1.
CD23 Binding (negative) of in lymphocytes
1) Confidence 0.13 Published 2008 Journal J Hematop Section Body Doc Link PMC2713483 Disease Relevance 1.48 Pain Relevance 0.26
The cross-linking of CD23 on macrophages or on other CD23-bearing effector cells by IgE-containing immune complexes is thought to play a pathogenic role in malaria via TNF-mediated pathways [16].
CD23 Binding (linking) of in macrophages associated with malaria
2) Confidence 0.11 Published 2007 Journal Malar J Section Body Doc Link PMC1781948 Disease Relevance 0.40 Pain Relevance 0.08
Omalizumab (Xolair®, Novartis Pharma AG) is a recombinant DNA-derived humanized immunoglobulin G (IgG) 1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE) and has been developed for the treatment of allergic asthma.
immunoglobulin E Binding (binds) of associated with asthma
3) Confidence 0.09 Published 2008 Journal Core Evidence Section Body Doc Link PMC2899803 Disease Relevance 0.35 Pain Relevance 0.06
BACKGROUND: Neuromuscular blocking agents (NMBAs) can cause anaphylaxis through immunoglobulin E (IgE) antibodies that bind quaternary ammonium ion epitopes.
immunoglobulin E Binding (bind) of associated with anaphylaxis
4) Confidence 0.01 Published 2007 Journal Allergy Section Abstract Doc Link 17983379 Disease Relevance 0.26 Pain Relevance 0
It selectively binds to circulating immunoglobulin E (IgE) and, thereby, prevents binding of IgE to mast cells and other effector cells.
immunoglobulin E Binding (binds) of in mast cells
5) Confidence 0.01 Published 2004 Journal Treat Respir Med Section Abstract Doc Link 15219177 Disease Relevance 0.40 Pain Relevance 0.13
It selectively binds to circulating immunoglobulin E (IgE) and, thereby, prevents binding of IgE to mast cells and other effector cells.
immunoglobulin E Binding (binds) of in mast cells
6) Confidence 0.01 Published 2004 Journal BioDrugs Section Abstract Doc Link 15571425 Disease Relevance 0.40 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox